NACDS Foundation unveils application process for Community PREP
ALEXANDRIA, Va. — In an effort to create 30 new community pharmacy residency positions by funding programs across the nation, the charitable arm of the National Association of Chain Drug Stores announced the grant application, review and approval process for its Community Pharmacy Residency Expansion Project.
The NACDS Foundation said that Community PREP, which first was announced in December 2010, will award 15 grants to nonprofit academic institutions, totaling $50,000 each.
“The NACDS Foundation is pleased to provide this much-needed funding to create and expand community pharmacy residency programs throughout the United States,” NACDS Foundation president Edith Rosato said. “These patient-focused residency programs will help cultivate pharmacy graduates’ abilities to provide innovation in the delivery of patient care services under the expert guidance of community pharmacy preceptors.”
Click here for more information on the Community PREP program.
Three H.D. Smith executives promoted
SPRINGFIELD, Ill. — Pharmacy wholesaler H.D. Smith has promoted three of its executives.
The company announced Wednesday the promotion of Joseph Conda to SVP strategic planning and business development, Robert Appleby to corporate VP prescription products and Carolyn Webb to corporate VP marketing.
“The focus of these top performers enables the company to maximize growth potential and continue to raise the bar in providing exceptional service to customers,” H.D. Smith chairman and CEO Dale Smith said. “Combined, they bring more than 70 years of sales, product and industry leadership counsel and experience to serve our customers.”
Victoza, NovoSeven drive Novo Nordisk’s sales
BAGSVÆRD, Denmark — A collection of relatively new products helped drive up sales and profits at Novo Nordisk, the Danish drug maker said Wednesday.
Sales increased by 22% in the North American markets when measured in local currencies, and by 29% when measured in Danish kroner, the company said. Operating profits were $3.5 billion, a 16% increase over 2009.
Strong performers included the Type 2 diabetes drug Victoza (liraglutide), which had sales of $429.4 million, while sales of the hemophilia treatment NovoSeven (coagulation factor VIIa [recombinant]) increased by 8%.
“2010 was a very good year for Novo Nordisk with strong organic sales growth driven by the modern insulins and Victoza,” Novo Nordisk president and CEO Lars Rebien Sørensen said. “We expect continued sales growth from these products and are encouraged by the results from the phase-3 program with our new generation insulins.”